Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier for advanced OPTIONS screeners and volatility tools. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Intellia Thera CS (NTLA)

Intellia Thera CS (NTLA)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Profile for [[ item.sessionDateDisplayLong ]]

Company Info

Intellia Thera CS 40 Erie Street Suite 130 Cambridge MA 02139 USA

www.intelliatx.com Employees: 403 P: 857-285-6200

Sector:

Medical

Description:

Intellia Therapeutics is a leading clinical-stage genome editing company focused on developing CRISPR/Cas9-based therapeutics. The company is pursuing two primary approaches to fully realize the transformative potential of CRISPR/Cas9 in vivo programs that use intravenously administered CRISPR as the therapy and ex vivo programs that use CRISPR to create the therapy by using engineered human cells.'

Key Statistics

Overview:

Market Capitalization, $K 1,447,875
Enterprise Value, $K 1,258,695
Shares Outstanding, K 115,830
Float, K 112,239
% Float 96.90%
Short Interest, K 40,578
Short Float 35.03%
Days to Cover 10.40
Short Volume Ratio 0.49
% of Insider Shareholders 3.10%
% of Institutional Shareholders 88.77%

Financials:

Annual Sales, $ 57,880 K
Annual Net Income, $ -519,020 K
Last Quarter Sales, $ 13,780 K
Last Quarter Net Income, $ -101,320 K
EBIT, $ -478,740 K
EBITDA, $ -468,450 K

Growth:

1-Year Return 32.70%
3-Year Return -63.07%
5-Year Return -83.19%
5-Year Revenue Growth 34.29%
5-Year Earnings Growth -133.18%
5-Year Dividend Growth 0.00%

Per-Share Information:

Most Recent Earnings -0.92 on 11/06/25
Next Earnings Date 02/26/26
Earnings Per Share ttm -4.25
EPS Growth vs. Prev Qtr 7.07%
EPS Growth vs. Prev Year 31.34%
Annual Dividend & Yield (Paid) 0.00 (0.00%)
Annual Dividend & Yield (Fwd) 0.00 (0.00%)
Dividend Payout Ratio 0.00%

NTLA Ratios

Ratio
Price/Earnings ttm 0.00
Price/Earnings forward N/A
Price/Earnings to Growth N/A
Return-on-Equity % -57.01%
Return-on-Assets % -44.39%
Profit Margin % -896.72%
Debt/Equity 0.00
Price/Sales 22.78
Price/Cash Flow N/A
Price/Book 1.70
Book Value/Share 6.97
Interest Coverage -3.12
60-Month Beta 2.05
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar